Bacopa monnieri for Attention & Focus Difficulties
C Some Evidence Limited evidence from small studies, but some positive signals exist.Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
The Bottom Line
Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
Key Study Findings
Population: ADHD patients (systematic review of supplements)
Population: Healthy older adults
Population: Retracted publication - invasive ductal carcinoma
Population: None
Population: None
Population: None
Key Statistics
8
Studies
600
Participants
Positive
Grade
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Commonly Used Dosages
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
Upper limit: Not established; well-tolerated up to 600 mg/day in trials
Dosages Studied in Research
| Dosage | Duration | Effect | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | 1861 |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
Best taken: With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
Reported Side Effects
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
Known Interactions
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
Tolerable upper intake: Not established; well-tolerated up to 600 mg/day in trials
Always consult your healthcare provider before starting any supplement.
Frequently Asked Questions
Does Bacopa monnieri help with Attention & Focus Difficulties?
How much Bacopa monnieri should I take for Attention & Focus Difficulties?
Are there side effects of Bacopa monnieri?
How strong is the evidence for Bacopa monnieri and Attention & Focus Difficulties?
Related Evidence
Other ingredients for Attention & Focus Difficulties
Bacopa monnieri for other conditions
References
- [1] Shatha Al Shahab et al.. Nutrients. 2025. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review. doi:10.3390/nu17091482 PubMed
- [2] Xueyan Feng et al.. Front Pharmacol. 2025. The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of … doi:10.3389/fphar.2025.1672171 PubMed
- [3] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [4] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
- [5] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [6] Andrea Brioschi Guevara et al.. Alzheimers Res Ther. 2021. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. doi:10.1186/s13195-021-00844-1 PubMed
- [7] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [8] Grace M McPhee et al.. Med Hypotheses. 2016. Cognitive training and Bacopa monnieri: Evidence for a combined intervention to alleviate age associated cognitive decline. doi:10.1016/j.mehy.2016.09.002 PubMed
- [9] Ananya Sadhu et al.. Clin Drug Investig. 2014. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. doi:10.1007/s40261-014-0235-9 PubMed
- [10] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.